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Abstract: Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by 
blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor 
(VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, 
which are important targets in thyroid cancer (TC). It is emerging as a potentially effective 
option in the treatment of advanced medullary thyroid cancer (MTC) and in dedifferentiated 
papillary thyroid cancer not responsive to radioiodine. The most important effect of vandetanib 
in aggressive MTC is a prolongation of progression-free survival and a stabilization of the 
disease. Significant side effects have been observed with the vandetanib therapy (as fatigue, 
hypertension, QTc prolongation, cutaneous rash, hand-and-foot syndrome, diarrhea, etc), 
and severe side effects can require the suspension of the drug. Several studies are currently 
under way to evaluate the long-term efficacy and tolerability of vandetanib in MTC and in 
dedifferentiated papillary TC. The efficacy of vandetanib in patients with MTC in long-term 
treatments could be overcome by the resistance to the drug. However, the effectiveness of 
the treatment could be ameliorated by the molecular characterization of the tumor and by the 
possibility to test the sensitivity of primary TC cells from each subject to different tyrosine 
kinase inhibitor. Association studies are evaluating the effect of the association of vande-
tanib with other antineoplastic agents (such as irinotecan, bortezomib, etc). Further research 
is needed to determine the ideal therapy to obtain the best response in terms of survival and 
quality of life.
Keywords: vandetanib, medullary thyroid cancer, papillary thyroid cancer, tyrosine kinase 
inhibitors, adverse events
Introduction
Thyroid cancer (TC) accounts for about 1% of all cancers1 and is the most common 
malignant endocrinological tumor.2 In the last few decades, an increased TC incidence 
has been shown (from 10.3 per 100,000 individuals in 2000 to 21.5 per 100,000 
individuals in 2012),3 especially for papillary carcinoma, while mortality seems not 
changed.
The increased incidence of TC is probably due to more sophisticated diagnostic 
procedures (ultrasonography, fine-needle aspiration [FNA], etc), but also environmental 
factors have been implicated (radiation exposure, pollutants, etc). Furthermore, new 
risk factors have emerged in the last decade.4,5 Histologically, TCs include different 
subtypes (Table 1).6–16
Molecular pathways in TC
In the last few decades, several molecular pathways involved in the development of 
TC have been identified.17
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Rat sarcoma
Rat sarcoma (RAS) genes encode proteins activating MAPK 
and PI3K pathways (Figure 1). RAS activation depends 
on epidermal growth factor receptor (EGFR), and is often 
overexpressed if mutated. RAS mutations are more frequent 
in follicular thyroid cancer (FTC) and in half of anaplastic 
thyroid cancer (ATC) and poorly differentiated thyroid 
cancer (PDTC), while they are present in only 10%–15% 
of papillary thyroid cancer (PTC; especially in follicular 
variant).16,18,19 Somatic RAS mutations are also found in 
medullary thyroid cancer (MTC) without RET (REarranged 
during Transfection) mutations.20
BRAF is a member of RAF family proteins that binds 
RAS and activates MAPK cascade. Valine to glutamate 
amino acid substitution at residue 600 (V600E) is the most 
frequent point mutation (45% of PTC, 10%–20% of PDTC, 
20% of ATC, rarely in FTC) that is associated with tumor 
recurrence, absence of tumor capsule, and loss of response 
to radioiodine (RAI).21 Other BRAF mutation or rearrange-
ments (as AKP9/BRAF) are less frequent.
ReT (Rearranged during Transfection)
RET is a proto-oncogene (10q11.2), which codes for a 
tyrosine kinase transmembrane receptor and is expressed 
on tissues deriving from the neural crest including thyroid 
C cells but not in normal thyroid follicular cells.22,23 In 
thyroid tumors, RET can be activated by point mutations 
in C cells or by rearrangements (fusion to other genes) in 
epithelial cells.16
RET/PTC rearrangements (the 3′ portion of RET gene is 
fused to the 5′ portion of various genes) activate transcription 
of the RET tyrosine kinase domain inducing uncontrolled 
proliferation.24,25 Approximately 20%–40% of sporadic 
PTC are found RET/PTC rearrangements,26 that are also 
present in thyroid adenomas and benign lesions.27,28 Among 
13 RET/PTC rearrangements reported, RET/PTC1 (by the 
fusion with the CCDC6, formerly H4) and RET/PTC3 (by 
the fusion with the NCOA4, formerly ELE1) are the most 
common.29
Some authors have suggested a role of RET/PTC in the 
initial step of childhood PTC or in PTC arising after expo-
sure to ionizing radiations (mainly RET/PTC3).30,31 RET/
PTC3 appears to be related with poor prognostic factors, 
such as a greater tumor size and a more advanced stage at 
diagnosis.32
Activating mutations involving RET have been identi-
fied in 98% of hereditary MTC and 50% of sporadic MTC.33 
Germ line gain of function RET mutations are found in 98% 
multiple endocrine neoplasia type 2A (MEN2A) families, 
85% familial medullary thyroid cancer (FMTC), and more 
Table 1 Histological thyroid cancer subtypes
Histological thyroid cancer subtypes Description
DTC
[PTC (80% cases); FTC (11% cases); Hürthle cells TC]
Tumor dedifferentiation in DTC occurs in up to 5% of tumors and it is 
associated with a more aggressive behavior and loss of iodide uptake
PDTC it is a subset of thyroid tumors more aggressive than DTC
ATC Highly aggressive, undifferentiated thyroid cancer (2% of all TCs)
MTC
[Sporadic (75%) or hereditary (25%); hereditary MTC 
might be (a) FMTC, defined by the presence of MTC 
alone; (b) involved in MeN2 syndrome]
it is derived from C cells (2%–5% of all TCs)
Lymphomas and sarcomas Rare TCs
Abbreviations: DTC, differentiated thyroid cancer from follicular cells; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; TC, thyroid cancer; PDTC, poorly 
differentiated thyroid cancer; ATC, anaplastic thyroid cancer; MTC, medullary thyroid cancer; FMTC, familial medullary thyroid cancer; MeN2, multiple endocrine neoplasia 
type 2.
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Figure 1 The RAS/MAPK/Pi3K pathway.
Abbreviation: RAS, rat sarcoma.
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than 98% multiple endocrine neoplasia type 2B (MEN2B).34 
In MEN2A, the most frequent mutation of RET is in cysteine 
634,35 while the most common mutations associated with 
MEN2B are M918T and A883F.35–37
In sporadic MTC, the substitution of methionine by threo-
nine at codon 918 (M918T) is the most common mutation 
and is associated with a more aggressive disease and poorer 
prognosis.38,39
Rearrangements of PAX8/peroxisome proliferator–
activated receptor γ is detected in 30%–40% of FTC and 
2%–13% of follicular adenomas.40,41
vascular endothelial growth factor
Angiogenesis plays a crucial role for growth and metasta-
sis of a tumor; in fact, several studies showed correlation 
between angiogenesis and tumor aggressiveness.42,43 The 
vascular endothelial growth factor (VEGF) family includes 
VEGF A-C and placental growth factor (P1GF) and stimu-
lates angiogenesis, endothelial cell proliferation, migration, 
survival, and vascular permeability binding to the VEGF 
receptors: VEGFR-1, VEGFR-2, and VEGFR-3.44 VEGF 
signal is mediated mainly by VEGFR-2 receptor, expressed 
at high levels by endothelial cells involved in angiogenesis.45 
VEGFR-2 stimulation results in activation of different path-
ways, including MAPK and PI3K-Akt.46 An overexpression 
of VEGF and angiopoietin-247 has been shown in DTC, 
while in MTC, overexpression of VEGF and VEGFR-2 was 
found.48 Also, there is an increased expression of VEGF-C 
and VEGFR-3 in metastatic MTC.49 Increased VEGF expres-
sion is associated with a worse prognosis in many DTC.50 
Furthermore, overexpression and activation of VEGFR-2 in 
MTC correlate with metastasis.39 In experimental models, 
drugs interfering with VEGF block the growth of DTC and 
PDTC.51–53 These discoveries have led to the development of 
systemic antiangiogenic drugs that act on VEGF-A pathway, 
for the treatment of patients with various types of cancers 
including TC.54
epidermal growth factor
Epidermal growth factor is also important for the growth and 
metastasis ability of the tumor and acts by binding to EGFR, 
thus stimulating VEGF expression.55 In TC, EGFR (ErbB-1; 
HER1 in human beings) mutations contribute to RET kinase 
activation and favor growth and spread of tumor; in turn, 
activation of RET/PTC1 and RET/PTC3 induces expression 
of EGFR.56,57
The incidence of EGFR mutations in TC was previously 
thought to be low, but more recently, it has been suggested that 
EGFR mutations are almost 30%.58 EGFR is overexpressed and 
correlated with tumor progression and lymph node metastasis 
in ATC and PDTC, compared to normal thyroid tissue.59–61 Lote 
et al have described a case of metastatic PDTC with an EGFR 
mutation, treated with erlotinib (selective EGFR tyrosine 
kinase inhibitor [TKI]) and responsive to therapy, suggesting 
the importance of EGFR as therapeutic target in PDTC.62 In 
PTC, the expression of EGFR-1 protein is absent or poor. It 
suggests that overexpression of EGFR-1 can favor progression 
toward an angiogenic, poorly differentiated, thyroid-stimulating 
hormone (TSH)-independent phenotype.63
Thyroid carcinoma therapy
Differentiated thyroid carcinoma
DTC is treated by surgery, followed by RAI in selected 
patients and levothyroxine therapy in all patients.64 Gener-
ally, patients with DTC have a good prognosis, with a 5-year 
survival rate of 97.8%, when properly treated.65 However, 
5% of patients have distant metastasis at the diagnosis or 
recurrent disease that cannot be treated with surgery and/or 
are resistant to RAI (because during progression, tumor cells 
lose RAI uptake ability).66,67
For patients with metastatic disease, the NCCN Thyroid 
Carcinoma Panel recommends individualized treatment 
based on tumor location. Although not curative, systemic and/
or locoregional therapy may be recommended for patients 
with symptomatic and/or progressive disease who cannot be 
treated with RAI.68 Systemic therapy (including cytotoxic 
chemotherapy) can be considered for tumors not surgically 
resectable, not responsive to RAI, and not treatable with 
external beam radiation therapy or that have shown progres-
sion during the past 6–12 months.15 However, conventional 
chemotherapy and radiotherapy often have a modest effect 
on aggressive TC.6
TKIs represent an option of systemic treatment in case 
of progressive, aggressive refractory cancers.69
Medullary thyroid carcinoma
MTC prognosis varies in relation to the extension of the tumor 
and RET mutations. MEN2A and FMTC patients commonly 
have a better treatment outcome than those with sporadic 
MTC, who are frequently diagnosed at a more advanced stage. 
Three risk levels related RET mutations have been identified. 
Level 1 (low risk) includes patients with RET codon 768, 
790, 791, 804, and 891 mutations; level 2 (high risk), patients 
with MEN2A/FMTC-related mutations (codon 609, 611, 618, 
620, 630, and 634); and level 3 (very high risk), patients with 
MEN2B mutations in codon 883 or 918.26
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Generally, MTC is curable by surgery in an early stage, 
followed by postoperative levothyroxine therapy. No curative 
systemic therapy exists for locally advanced and metastatic pro-
gressive MTC that does not respond to conventional cytotoxic 
chemotherapy. TKIs are actually recommended for selected 
patients with recurrent or persistent aggressive MTC.15,69,70
Tyrosine kinase inhibitors
TKIs act by blocking the ATP site of the tyrosine kinase recep-
tors, preventing tyrosine kinase activation.19 Already, several 
TKIs are used in the treatment of various advanced cancers.
Whereas TKIs do not act selectively on pathways specific 
for a tumor, they have been tested on different tumors includ-
ing DTC, MTC, and ATC.71 TKIs improve progression-free 
survival (PFS) and stable disease (SD) rates in TC.72
It has been demonstrated that TKIs have a clinically 
significant activity in randomized, placebo-controlled clinical 
trials in locally recurrent unresectable and metastatic MTC 
and in RAI refractory DTC. Particularly, in aggressive 
DTC, or MTC, several studies have evaluated the use of axi-
tinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitinib, 
cabozantinib, and vandetanib.73 Sorafenib and lenvatinib are 
currently approved by the US Food and Drug Administration 
(FDA) and EMA for the treatment of aggressive DTC, while 
vandetanib and cabozantinib are used for the treatment of 
aggressive advanced MTC.74–76
Cabozantinib is an oral once-daily multitarget TKI of 
MET, VEGFR-2, RET, acting against KIT, AXL, FLT3, and 
Tie-2.77 In a Phase III clinical study, cabozantinib improved 
PFS of patients with MTC, and it is actually approved by 
FDA and EMA for the treatment of aggressive MTC.76 Cabo-
zantinib has also been evaluated in metastatic DTC patients, 
because they have activation on tyrosine kinases, including 
MET, VEGFR-2, and RET, suggesting the possible use of 
cabozantinib in metastatic DTC.78
Actually, studies focus on refining combination treatment 
strategies and determining which patients will obtain the best 
benefit from TKIs (with the least toxicity).79
vandetanib
Vandetanib (Caprelsa, ZD6474; AstraZeneca) is an oral 
once-daily TKI that works by blocking RET, VEGFR-2, 
VEGFR-3, and EGFR and to a lesser extent VEGFR-1, which 
are important targets in TC (Figure 2).80
Thyroid tumor cell
RET
RAS PI3K
BRAFCRAF
MEK AKT
ERK mTOR NFkB
IKK
STAT
JAK
RAS PI3K
BRAF AKT
MEK
mTOR
ERK
Transcription factors Transcription factors
EGFR VEGFR3 VEGFR2
Endothelial cell
Vandetanib
Downstream cellular effects:
Downstream cellular effects:� Proliferation
� Survival
� Migration
� Differentiation
� Proliferation
� Survival
� Migration
� Differentiation
� Growth
Figure 2 Molecular pathways involved in the development of thyroid cancer and action of vandetanib.
Abbreviations: ReT, Rearranged during Transfection; eGFR, epidermal growth factor receptor; veGFR, vascular endothelial growth factor receptor.
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Initially, it was shown that vandetanib blocks the enzy-
matic activity of RET-derived oncoproteins and in vivo 
phosphorylation and signaling of the RET/PTC3 and RET/
MEN2B oncoproteins and of an epidermal growth factor-
activated EGFR/RET chimeric receptor. Vandetanib inhib-
ited the proliferation of two human PTC cell lines that carry 
spontaneous RET/PTC1 rearrangements. Finally, it blocked 
formation of tumors in vivo after injection of RET/PTC3-
transformed NIH3T3 fibroblasts into nude mice.81
Also, most of the mutant oncoproteins (RET/E768D, 
RET/L790F, RET/Y791F, RET/S891A, and RET/A883F) 
were found sensitive to vandetanib, while mutations substi-
tuting valine 804, either to leucine or to methionine (as occur 
in some cases of MEN2A), were significantly resistant.82
Furthermore, it was shown that vandetanib was able to inhibit 
the growth of a transplantable MTC (from a sporadic human 
MTC carrying a RET C634R mutation) in nude mice.83
The most important antitumoral effect of vandetanib, 
in vivo, is an “indirect” effect on angiogenesis, interfer-
ing with EGFR-induced production of angiogenic growth 
factors.84,85
Several clinical trials have been conducted to evaluate 
the efficacy and tolerability of vandetanib in patients with 
TC (Table 2).
Phase i trials
The first Phase I trial was conducted on 77 patients with 
advanced solid tumors (not including MTC), treated with 
vandetanib; this study concluded that 500 mg/day was the 
maximum tolerated dose and once-daily oral dosing of 
300 mg/day was generally well tolerated.86 A Phase I trial, 
carried on 18 patients, established the maximum tolerated 
dose at 400 mg/day. In both trials, the authors recommended 
a dose of 300 mg/day.87
Phase ii trials
Medullary thyroid cancer
A Phase II, single-arm trial evaluated the efficacy of treat-
ment with vandetanib (300 mg/day) in 30 adult patients 
with unresectable, locally advanced, or metastatic hereditary 
MTC. In this study, the majority of patients had MEN2A 
(70%); RET mutations were located in codons: 634 (33% 
of patients), 618 (27%), 620 (13%), 918 (13%), 791 (7%), 
768 (3%), and 891 (3%). In this study, objective partial 
response (PR) was observed in 20% of patients and 53% of 
patients had SD for a median of 24 weeks with a manage-
able adverse event (AE) profile. There was no apparent 
association between RET germ line mutation and response 
to vandetanib treatment.88
Another trial investigated efficacy and safety of van-
detanib at 100 mg/day (or up to 300 mg/day in cases with 
disease progression) in 19 patients with advanced hereditary 
MTC and the results were similar to the previous study 
(PR in 16% and SD in 53% of patients for 24 weeks).89 
Both trials showed important reduction ($50%) in CEA 
and calcitonin levels; the latter did not correlate with the 
degree of tumor growth inhibition. It was suggested that 
CEA levels may be a better marker of tumor response to 
vandetanib.
Recently, a Phase I/II trial has been conducted for 
adolescents (13–18 years) and children (5–12 years) with 
metastatic or locally advanced MTC. In this trial, 16 patients 
were treated with vandetanib 100 mg/m2/day, concluding that 
this dosage is a well-tolerated and highly active treatment for 
adolescents and children with locally advanced or metastatic 
MTC and MEN2B.90
Differentiated thyroid cancer
Leboulleux et al91 carried out a double-blind, Phase II, 
randomized trial, in 145 patients with metastatic or locally 
advanced DTC (papillary, follicular, or poorly differenti-
ated) evaluating efficacy of vandetanib (300 mg/day) vs 
placebo (72 patients were allocated in vandetanib arm and 
73 patients in placebo arm). PFS (primary endpoint) in van-
detanib group was 11.1 months compared to 5.9 months in 
placebo group, while PR was 8% and 5% respectively, and 
SD 57% vs 42%. Better results have occurred in PTC than 
in FTC and PDTC.91
Table 2 Clinical trials of vandetanib in patients with thyroid cancer
Authors  
and references
Drug Thyroid  
cancer
Responses
PR SD PD PFS (months)
wells et al88 vandetanib 30 MTC 20% 53% 3% 27.9
Robinson et al89 vandetanib 19 MTC 16% 53% 16% 5.6
Leboulleux et al91 vandetanib 145 DeTC 8% 57% 11.1
wells et al92 vandetanib 231 MTC 45% 42%
Chougnet et al95 vandetanib 60 MTC 20% 55% 12% 16.1
Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; MTC, medullary thyroid cancer; DeTC, dedifferentiated 
thyroid cancer.
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Phase iii trials
A randomized, double-blind, placebo-controlled multicenter 
Phase III trial (ZETA trial) was conducted in 331 advanced 
(5% of all patients) or metastatic (95%) MTC patients.92 
In this study, all MTC patients were offered the option 
of receiving vandetanib (300 mg daily administered until 
disease progression) in an open-label phase. Ten percent of 
patient had hereditary MTC, while 90% sporadic or unknown 
origin MTC. Also, 56% of patients were RET mutation posi-
tive, 2% RET mutation negative, and 41% unknown. The 
results of this study showed better PFS in the vandetanib 
group compared to placebo (30.5 vs 19.3 months; P,0.001), 
while OS was not significantly changed and calcitonin (69% 
vs 3%) and CEA (52% vs 2%) response rates were higher 
(P,0.001) in patients receiving vandetanib. Patients with 
sporadic MTC (RET positive) benefited from vandetanib and 
there was a good response in patients with M918T-negative 
tumors and in RET unknown status.92
Because vandetanib is effective in stabilizing symptom-
atic and/or progressive disease, it was approved, since April 
(FDA) and November (European Union) 2011, for the treat-
ment of unresectable, locally advanced or metastatic MTC in 
patients with symptomatic or progressive disease, in Europe 
and the United States.93
Recently, a retrospective study showed efficacy of vande-
tanib in the treatment of eleven progressive metastatic MTC 
patients with 36% PR.94
Moreover, a recent French study conducted to describe 
the toxicity profile and efficacy of vandetanib treatment 
outside any trial showed vandetanib efficacy in advanced 
MTC patients, but in consideration of the appearance of 
at least one AE in all patients, a careful monitoring was 
recommended.95
Actually, a new randomized, double-blind, placebo-
controlled, multicenter Phase III study is ongoing in DTC 
patients.96
Also, a first Phase IV randomized trial is ongoing to 
evaluate differences in the response in MTC patients treated 
with 300 mg/day vs 150 mg/day of vandetanib.97
Safety and tolerability
Clinical studies showed that vandetanib treatment is associ-
ated with several AEs but it has an acceptable tolerability 
because AEs are generally mild and manageable. The most 
frequent AEs in vandetanib-treated patients are diarrhea, rash 
and folliculitis, nausea, QTc prolongation, hypertension and 
fatigue, headache, decreased appetite, and acne (diarrhea, 
hypertension, prolongation QTc, and fatigue were the most 
common AEs of at least grade 3).88–92 In the management of 
AEs, it is important to remember that the half-life of vande-
tanib is 19 days.98,99 Dose reduction can induce AEs grade 1 
or 2 improvement, but for AEs grade 3 or 4, it is advisable 
to interrupt vandetanib until AEs resolve, then therapy might 
be resumed but at a lower dose.89
Moreover, vandetanib treatment requires increased thy-
roxine, calcium, and vitamin D analog.100
Dermatological Aes
Several trials showed a high incidence of dermatological 
AEs in patients treated with vandetanib. In the ZETA 
trial, in fact, these AEs occurred in 45% of cases.92 Van-
detanib, as other EGFR inhibitors, is associated especially 
with a papulopustular eruption. The development of the 
rash is related to EGFR inhibition by vandetanib (in fact, 
EGFRs are abundantly expressed in the epidermis and 
its appendages)101,102 that induces hyperkeratosis, follicle 
obstruction, and then inflammation of the pilosebaceous 
follicle.103
In a review of 2,961 MTC patients treated with vande-
tanib, incidence of all-grade and high-grade rash was 46.1% 
and 3.5%, respectively.104
Other dermatological AEs associated to the treatment 
with vandetanib are photosensitivity (observed in all 
patients), xerosis, hair changes, paronychia, genital skin 
reactions, finger clefts, subungual splinter hemorrhages, and 
blue dots.105,106 AEs less frequently observed are mucositis, 
erythrodysesthesia, and pruritus,107 and in one case, Stevens-
Johnson syndrome has been described.108
Recently, a study confirmed that dermatologic AEs in 
children treated with target anticancer therapy (including 
vandetanib) are similar to those in adults.109
Generally, dermatological AEs are easily manageable, but 
given the high incidence of these dermatological AEs, their 
prevention and early management are important to reduce the 
risk of vandetanib dose reduction or interruption.110
Gastrointestinal Aes
Diarrhea is the most frequent gastrointestinal AE in patients 
treated with vandetanib during ZETA trial (56% of all 
patients), followed by nausea (33% of cases), decreased 
appetite (21%), vomiting (14%), and abdominal pain (14%).92 
Often, these AEs (especially diarrhea) cause poor patient 
compliance and treatment interruption. Patient education is 
important with dietary measures.
Sometimes, diarrhea in MTC may be due to excessive 
hormone production by tumor, which accelerates intestinal 
transit; in these cases, it improves with vandetanib treatment. 
In most cases, treatment with vandetanib causes diarrhea, 
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which can be rectified by correct hydration and possibly by 
administering loperamide.
For the treatment of nausea, the use of 5-HT3 antagonists 
(ondansetron) is not recommended as it might increase the risk 
of prolongation of the QTc interval.111 For the same reason, 
metoclopramide should also be used with caution.102 In the 
antiemetic therapy, an alternative may be palonosetron.112
When gastrointestinal AEs are severe, vandetanib should 
be stopped until symptoms improve.102,113
Cardiovascular Aes
Vandetanib treatment may induce development of cardio-
vascular AEs including hypertension, bleeding, arterial 
thrombosis, ventricular dysfunction, fatal cardiac failure, and 
QTc interval prolongation.114,115
In a systematic review and meta-analysis of 3,154 
patients treated with vandetanib, incidences of all-grade and 
high-grade hypertension in patients were 24.2% (95% con-
fidence interval, 18.1%–30.2%) and 6.4% (95% confidence 
interval, 3.3%–9.5%), respectively, with a higher incidence 
of all-grade hypertension in MTC patients than non-MTC 
patients.116 Because of this risk of hypertension, adequate 
blood pressure monitoring and therapy with ACE inhibi-
tors (if necessary) is recommended in patients being treated 
with vandetanib. If blood pressure is not controlled, calcium 
antagonist and beta blockers can be used.102
A cardiological very important AE in vandetanib treat-
ment (and TKIs therapy) is QTc prolongation. Particularly 
QTc .500 ms was observed in 14% of patients treated with 
vandetanib in the ZETA trial; two cases of death in patients 
with QTc .550 ms have been reported (one due to sepsis 
and one due to heart failure).99
Before starting vandetanib treatment, ECG and echocar-
diogram are recommended and vandetanib must not be started 
in patients with QTc .450 ms (US) or .480 ms (European 
Union). During therapy, coadministration of drugs which 
prolong QTc interval should be avoided. Also, electrolyte 
levels and serum TSH should be maintained in normal 
range. Usually, QTc interval prolongation is relatively mild 
at clinical doses and has not led to appreciable morbidity 
clinically,115 although because of the potential for QT pro-
longation, torsades de pointes, and sudden death, vandetanib 
is restricted via a Risk Evaluations and Mitigation Strategy 
program.93
Other Aes
Other common side effects of vandetanib include fatigue, 
headache, hypocalcemia, hypoglycemia, increased transami-
nase levels, and thyroid dysfunction.102,117,118
Limits, drug resistance, and 
combination studies
Although therapy with TKIs is less toxic than chemotherapy, 
severe AEs require discontinuation of the drug. Further-
more, TKIs block tumor growth but do not eliminate it. 
Clinical trials have given contrasting results regarding the 
efficacy of TKIs in DTC patients: probably, these discordant 
results depend on mechanisms of drug resistance, via activa-
tion of alternative mitogenic signals.119 For this reason, studies 
are evaluating the combinations of TKIs targeting different 
pathways.120 Mechanisms of primary and acquired resistance 
to vandetanib have been investigated; actually, RET mutations 
cannot be used clinically to predict response in MTC.121
ZETA trials confirmed the clinical efficacy of vandetanib 
in patients with sporadic MTC tumors harboring the M918T 
mutation; while, the clinical efficacy of vandetanib in patients 
harboring other RET mutations needs other studies.
In vitro studies showed that the RET V804M and V804L 
mutations (that are rare and occur in sporadic and hereditary 
MTC) confer resistance to vandetanib82 and result clinically 
in primary or acquired resistance to vandetanib. However, 
sorafenib has shown activity against the V804 mutant 
in vitro.122
Moreover, other studies are needed to evaluate if Ras 
mutations, identified in 60%–80% of RET-negative spo-
radic MTC,123 confer clinical resistance to vandetanib. 
However, it has been shown (in vitro) that cell lines with 
acquired resistance to vandetanib present persistent activa-
tion of the Ras/Raf/MEK pathway (that can be abrogated 
by sorafenib).124
The response to therapy could be improved by testing the 
sensitivity of TC cells to different TKIs. In fact, in vitro drug 
screening with human primary neoplastic cells has a 60% pos-
itive predictive value of clinical response in vivo in the same 
patient and a 90% negative predictive; thus, the administration 
of inactive drugs could be avoided.125–129 More recently, it has 
been demonstrated that primary TC cell cultures from ATC 
(ANA) may be obtained from FNA opening the possibility to 
the use of FNA-ANA to test the chemosensitivity to different 
drugs in each patient (avoiding unnecessary surgical biopsies, 
until now used to obtain ANA).129–135
Combination studies
Several studies have evaluated the effectiveness of the syn-
ergic action of different antineoplastic drugs in combination 
studies.
It has been shown that combined therapy with bortezomib 
(proteasome inhibitor) and EGFR inhibitors (gefitinib, 
vandetanib, and cetuximab) induced (in EGFR-expressing 
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human cancer cell lines) a synergic inhibition of neoplastic 
growth.136 Currently, nonrandomized, Phase I/II trial of the 
combination of vandetanib plus bortezomib is recruiting 
patients with solid tumors (including MTC).137
Other studies have evaluated the combination of vande-
tanib and irinotecan. Preclinical data showed that vandetanib 
has antiproliferative antitumor activity in vitro, which acts in 
a sequence-dependent manner with chemotherapeutic agents, 
such as irinotecan, in colon cancer cell lines.138 A subsequent 
study was conducted in a murine xenograft model of human 
colon cancer treated with vandetanib in combination with 
irinotecan that showed an additive synergic effect of these 
drugs.139 Another study evaluated the response to vandetanib, 
radiotherapy, and irinotecan of human LoVo colorectal 
tumoral cells, demonstrating that vandetanib significantly 
increases the antineoplastic effects of irinotecan and radia-
tion when given in combination, resulting in a reduction of 
tumor growth.140 Recently, a Phase I trial was conducted in 
27 patients with metastatic colorectal cancer refractory to 
cytotoxic chemotherapy, treated with vandetanib, cetuximab, 
and irinotecan, showing no apparent increase of the efficacy 
with this combination.141 Several studies have recently sug-
gested that the PI3K/Akt/mTOR signaling pathway is impli-
cated in the pathogenesis and progression of neuroendocrine 
tumors and MTC. The deregulation of the PI3K/Akt/mTOR 
pathway seems to contribute to the tumorigenic activity of 
RET proto-oncogene mutations. Targeting this pathway 
through specific inhibitors at simple or multiple sites may 
represent an attractive potential therapeutic approach for 
patients with advanced MTCs. It has been recently suggested 
that the concomitant targeting of RET and mTOR may rep-
resent another innovative therapeutic strategy in MTC.142
Conclusion
Vandetanib is emerging as a potentially effective option in the 
treatment of advanced MTC. Furthermore, vandetanib seems 
to be a promising therapeutic option in patients with advanced 
dedifferentiated PTC that is not responsive to traditional 
therapies or RAI. The most important effect of vandetanib in 
aggressive MTC is a prolongation of PFS and a stabilization 
of the disease, while overall survival is not changed. Signifi-
cant side effects have been observed with vandetanib therapy 
(as fatigue, hypertension, QTc prolongation, cutaneous rash, 
mucositis, hand-and-foot syndrome, nausea, diarrhea, vomit-
ing, and thyroid dysfunction), and severe side effects can 
require the suspension of the drug. Several studies are currently 
under way to evaluate the long-term efficacy and tolerability 
of vandetanib in MTC, and in dedifferentiated PTC, because 
progression can be slow. The efficacy of vandetanib in patients 
with MTC in long-term treatments could be overcome by the 
resistance to the drug that could arise from the activation of 
alternate mitogenic signals. The effectiveness of the treatment 
could be ameliorated by the possibility to test the sensitivity of 
primary TC cells from each subject to different TKIs. In fact, 
disease-orientated in vitro drug screening permit to predict 
in vivo effectiveness in 60% of cases, while a negative chemo-
sensitivity test in vitro is associated with a 90% ineffectiveness 
of the chemotherapy in vivo, avoiding the administration of 
inactive (potentially toxic) drugs to these patients. Moreover, 
association studies are evaluating the effect of the associa-
tion of vandetanib with other antineoplastic agents (such as 
irinotecan, bortezomib, etc), in patients with various types 
of cancer. Further research is needed to determine the ideal 
targeted therapy, based on molecular characterization of the 
tumor and of the host factors, to obtain the best response in 
terms of survival and quality of life.
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